-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the increase in health awareness and aging of the people in our country, the demand for medicines will be on the rise in a relatively long period of time
.
APIs and pharmaceutical intermediates are located in the upper and middle reaches of the pharmaceutical industry chain.
They are the foundation of the pharmaceutical industry and one of the strategic pillars of China's pharmaceutical industry
.
Among them, in recent years, the application fields of nucleoside (acid) drugs have become wider and wider, and new products have continued to appear
.
It is reported that nucleoside products are widely used in the development and production of mRNA vaccines and drugs, oligonucleotide drugs, antiviral drugs, and nucleic acid in vitro detection reagents.
They have become important basic materials for the life science industry and play a significant role in the development of the global life science industry.
An important supporting role, the global nucleoside product market is showing a rapid development trend, and the future market size can be expected
.
In order to seize the new track of high value-added nucleoside APIs, Huadong Medicine recently acquired 100% of Huachang Hi-Tech
.
On December 29, Huadong Medicine issued an announcement that its wholly-owned subsidiary Sino-American Huadong participated in the bankruptcy and reorganization of Huachang Hi-Tech and became its reorganization investor
.
It is reported that the acquisition of Huachang Hi-Tech by Huadong Medicine will help the company develop a new industrialization platform focusing on nucleoside products, semi-synthetic antiparasitic drugs from microbial sources and other drugs, and further cultivate the field of industrial microbiology
.
The content of the announcement shows that the industrial microbiology sector of East China Pharmaceutical Co.
, Ltd.
is currently facing a good development opportunity.
In order to further expand the scale of industrialization, the company believes that Huachang Hi-Tech is located in the local fine chemical industrial park after many inspections and demonstrations.
The resources have a high potential for revitalization.
By transforming its existing equipment and facilities, it can quickly form the production capacity of APIs, high-end intermediates, and special functional chemicals required by the company's industrial microbial sector
.
In view of the above reasons, the company's wholly-owned subsidiary Sino-US Huadong participated in the bankruptcy and reorganization of Huachang Hi-Tech and became its reorganization investor
.
It is reported that, in accordance with the "Reorganization Investment Agreement", Huachang Hi-Tech will acquire 100% of its equity from Sino-US East China after bankruptcy and reorganization.
The original shareholders’ equity will be adjusted to zero.
Sino-US East China will invest 108 million yuan in the form of capital increase.
Used to pay and pay off the bankruptcy expenses, common-benefit debts and bankruptcy claims involved in the "Reorganization Plan" of Huachang Hi-Tech
.
Huadong Medicine stated that this transaction is in line with the company's overall strategic development direction of industrial microbiology
.
Huachang Hi-Tech will become a vital industrialization platform in the company's industrial microbiology field, providing a powerful boost to the globalization of industrial microbiology industry expansion
.
Huadong Medicine will use Huachang Hi-Tech as the main production base for nucleoside products, and implement related modified, protective nucleosides and triphosphorylated nucleosides and other product pipelines, and form corresponding commercial production capabilities
.
After the reorganization is completed, Huadong Pharmaceutical will fully revitalize and make full use of Huachang Hi-Tech’s location advantages and pharmaceutical R&D and production background, and through the advantages of Sino-US Huadong in corporate management, production research and development, and market expansion, it will establish Huachang Hi-Tech’s existing production facilities.
Based on equipment, transform it into a production base for high-end specialty pharmaceutical raw materials and intermediates, and special functional chemicals that meet international standards
.
At that time, Huachang Hi-Tech will become a new industrialization platform for Huadong Pharmaceutical to develop the field of industrial microbiology following the Majestic Health Microbes Big Health Industry Platform
.
It is understood that Huadong Pharmaceutical has excellent technology in the microbiology field.
With the successive landing of industrialization platforms, Huadong Medicine will continue to be released on a global scale
.
Huadong Pharmaceutical Holdings subsidiary Hunda Bio has formed a series of R&D pipelines for fermentation basic nucleosides, enzyme-converted nucleosides, modified nucleosides, protective nucleosides and triphosphorylated nucleosides, and realized the commercial development of toxins and modified nucleosides , Has become the world's leading supplier of modified nucleosides for mRNA drugs
.
In the future, Huadong Medicine will continue to build an "industrialized, large-scale, and international" industrial cluster in the field of industrial microbiology.
With a global perspective, it will continue to focus on high value-added areas in the upstream of the industrial chain, and horizontally expand the company's existing microbial technology applications.
Scenarios, vertical expansion of industrial microbial technology development height and large-scale production capacity, to open up a new blue ocean in the industrial microbial industry
.
It is understood that Huadong Pharmaceutical has been deeply involved in the field of industrial microbiology for more than 40 years, has a deep industrial foundation, and has distinct advantages in industrial microbiology.
It has successfully developed and manufactured a variety of microbial drugs and built a key technology system for the development and production of microbial products
.
And this investment in Huachang Hi-Tech will become another strong layout of Huadong Medicine to integrate into the industrial chain of industrial microbial medicine innovation and research and development.
.
It is reported that Sino-US Huadong plans to rationally plan Huachang Hi-Tech production lines and public systems and make new investments to activate Huachang Hi-Tech's production capacity and introduce new products.
This part of the work is expected to be completed before the end of March 2022
.
.
APIs and pharmaceutical intermediates are located in the upper and middle reaches of the pharmaceutical industry chain.
They are the foundation of the pharmaceutical industry and one of the strategic pillars of China's pharmaceutical industry
.
Among them, in recent years, the application fields of nucleoside (acid) drugs have become wider and wider, and new products have continued to appear
.
It is reported that nucleoside products are widely used in the development and production of mRNA vaccines and drugs, oligonucleotide drugs, antiviral drugs, and nucleic acid in vitro detection reagents.
They have become important basic materials for the life science industry and play a significant role in the development of the global life science industry.
An important supporting role, the global nucleoside product market is showing a rapid development trend, and the future market size can be expected
.
In order to seize the new track of high value-added nucleoside APIs, Huadong Medicine recently acquired 100% of Huachang Hi-Tech
.
On December 29, Huadong Medicine issued an announcement that its wholly-owned subsidiary Sino-American Huadong participated in the bankruptcy and reorganization of Huachang Hi-Tech and became its reorganization investor
.
It is reported that the acquisition of Huachang Hi-Tech by Huadong Medicine will help the company develop a new industrialization platform focusing on nucleoside products, semi-synthetic antiparasitic drugs from microbial sources and other drugs, and further cultivate the field of industrial microbiology
.
The content of the announcement shows that the industrial microbiology sector of East China Pharmaceutical Co.
, Ltd.
is currently facing a good development opportunity.
In order to further expand the scale of industrialization, the company believes that Huachang Hi-Tech is located in the local fine chemical industrial park after many inspections and demonstrations.
The resources have a high potential for revitalization.
By transforming its existing equipment and facilities, it can quickly form the production capacity of APIs, high-end intermediates, and special functional chemicals required by the company's industrial microbial sector
.
In view of the above reasons, the company's wholly-owned subsidiary Sino-US Huadong participated in the bankruptcy and reorganization of Huachang Hi-Tech and became its reorganization investor
.
It is reported that, in accordance with the "Reorganization Investment Agreement", Huachang Hi-Tech will acquire 100% of its equity from Sino-US East China after bankruptcy and reorganization.
The original shareholders’ equity will be adjusted to zero.
Sino-US East China will invest 108 million yuan in the form of capital increase.
Used to pay and pay off the bankruptcy expenses, common-benefit debts and bankruptcy claims involved in the "Reorganization Plan" of Huachang Hi-Tech
.
Huadong Medicine stated that this transaction is in line with the company's overall strategic development direction of industrial microbiology
.
Huachang Hi-Tech will become a vital industrialization platform in the company's industrial microbiology field, providing a powerful boost to the globalization of industrial microbiology industry expansion
.
Huadong Medicine will use Huachang Hi-Tech as the main production base for nucleoside products, and implement related modified, protective nucleosides and triphosphorylated nucleosides and other product pipelines, and form corresponding commercial production capabilities
.
After the reorganization is completed, Huadong Pharmaceutical will fully revitalize and make full use of Huachang Hi-Tech’s location advantages and pharmaceutical R&D and production background, and through the advantages of Sino-US Huadong in corporate management, production research and development, and market expansion, it will establish Huachang Hi-Tech’s existing production facilities.
Based on equipment, transform it into a production base for high-end specialty pharmaceutical raw materials and intermediates, and special functional chemicals that meet international standards
.
At that time, Huachang Hi-Tech will become a new industrialization platform for Huadong Pharmaceutical to develop the field of industrial microbiology following the Majestic Health Microbes Big Health Industry Platform
.
It is understood that Huadong Pharmaceutical has excellent technology in the microbiology field.
With the successive landing of industrialization platforms, Huadong Medicine will continue to be released on a global scale
.
Huadong Pharmaceutical Holdings subsidiary Hunda Bio has formed a series of R&D pipelines for fermentation basic nucleosides, enzyme-converted nucleosides, modified nucleosides, protective nucleosides and triphosphorylated nucleosides, and realized the commercial development of toxins and modified nucleosides , Has become the world's leading supplier of modified nucleosides for mRNA drugs
.
In the future, Huadong Medicine will continue to build an "industrialized, large-scale, and international" industrial cluster in the field of industrial microbiology.
With a global perspective, it will continue to focus on high value-added areas in the upstream of the industrial chain, and horizontally expand the company's existing microbial technology applications.
Scenarios, vertical expansion of industrial microbial technology development height and large-scale production capacity, to open up a new blue ocean in the industrial microbial industry
.
It is understood that Huadong Pharmaceutical has been deeply involved in the field of industrial microbiology for more than 40 years, has a deep industrial foundation, and has distinct advantages in industrial microbiology.
It has successfully developed and manufactured a variety of microbial drugs and built a key technology system for the development and production of microbial products
.
And this investment in Huachang Hi-Tech will become another strong layout of Huadong Medicine to integrate into the industrial chain of industrial microbial medicine innovation and research and development.
.
It is reported that Sino-US Huadong plans to rationally plan Huachang Hi-Tech production lines and public systems and make new investments to activate Huachang Hi-Tech's production capacity and introduce new products.
This part of the work is expected to be completed before the end of March 2022
.
